CompletedPhase 2NCT00039130
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Studying Burkitt lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- David Rizzieri, MDDuke University Medical Center Bone Marrow Transplant
- Intervention
- filgrastim(biological)
- Enrollment
- 105 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2002 – 2014
Study locations (30)
- Naval Medical Center - San Diego, San Diego, California, United States
- Tunnell Cancer Center at Beebe Medical Center, Lewes, Delaware, United States
- CCOP - Christiana Care Health Services, Newark, Delaware, United States
- Walter Reed Army Medical Center, Washington D.C., District of Columbia, United States
- University of Illinois Cancer Center, Chicago, Illinois, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
- Hematology Oncology Associates of the Quad Cities, Bettendorf, Iowa, United States
- Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
- Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
- Union Hospital Cancer Program at Union Hospital, Elkton, Maryland, United States
- Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
- Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
- Cancer Institute of New Jersey at Cooper - Voorhees, Voorhees Township, New Jersey, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00039130 on ClinicalTrials.govOther trials for Burkitt lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07069699Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC GeneNational Cancer Institute (NCI)
- RECRUITINGEARLY PHASE1NCT07429461Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaZhejiang University
- RECRUITINGEARLY PHASE1NCT06793241Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaZhejiang University
- RECRUITINGPHASE2, PHASE3NCT06764238Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNCT06796517Immunotherapy in LymphomaSung-Soo Park
- RECRUITINGPHASE1NCT06060782Thiotepa, Cyclophosphamide, Clarithromycin and CytarabineFifth Affiliated Hospital, Sun Yat-Sen University
- RECRUITINGPHASE2NCT06179524CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALLBeijing Yongtai Ruike Biotechnology Company Ltd
- RECRUITINGPHASE1NCT06056752QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaAnhui Provincial Hospital